520 Results

People

  1. Postow
    Postow
  2. Motzer
    Motzer
  3. Wolchok
    Wolchok
  4. Hellmann
    Hellmann
  5. Shoushtari
    Shoushtari
  6. Voss
    Voss
  7. Callahan
    Callahan
  8. Abou-Alfa
    Abou-Alfa
  9. Jones
    Jones
  10. Rosenberg
    Rosenberg

Groups

  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)
  7. GSK Faculty (83)
  8. Surgery (71)
  9. Gastrointestinal Oncology Service (65)
  10. Weinberg Fellows (61)
  1. "nivolumab"
Formats
  1. Journal Article (342)
  2. Review (93)
  3. Editorial (41)
  4. Meeting Abstract (18)
  5. Correspondence (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Book Section (4)
  9. Conference Paper (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)

More Groups

People
  1. Michael Postow (55)
  2. Robert Motzer (50)
  3. Jedd Wolchok (41)
  4. Margaret Callahan (28)
  5. Alexander Shoushtari (27)
  6. Matthew Hellmann (26)

More People

Years
  1. 2025 (35)
  2. 2024 (70)
  3. 2023 (75)
  4. 2022 (52)
  5. 2021 (45)
  6. 2020 (64)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (23)
  2. Journal of Clinical Oncology (22)
  3. Journal of Thoracic Oncology (21)
  4. Lancet Oncology (21)
  5. New England Journal of Medicine (19)
  6. Annals of Oncology (17)

More Publications

Publishers
  1. Elsevier Inc. (77)
  2. Elsevier Science, Inc. (50)
  3. Oxford University Press (35)
  4. Wiley Blackwell (32)
  5. Biomed Central Ltd (27)
  6. Nature Publishing Group (27)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Eganelisib, a first-in-class PI3Kγ inhibitor, in patients with advanced solid tumors: Results of the phase 1/1b MARIO-1 trial
    Journal Article

    Hong, D. S.; Postow, M.; Chmielowski, B.; Sullivan, R.; Patnaik, A.; Cohen, E. E. W.; Shapiro, G.; Steuer, C.; Gutierrez, M.; Yeckes-Rodin, H.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: A CIBMTR analysis
    Journal Article

    Ragon, B. K.; Shah, M. V.; D’Souza, A.; Estrada-Merly, N.; Gowda, L.; George, G.; de Lima, M.; Hashmi, S.; Kharfan-Dabaja, M. A.; Majhail, N. S.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Pigment Cell & Melanoma Research (2023)

    Fulltext@MSK | Save
  • Prolonged generalized immune response on (18)F-FDG PET/CT following COVID-19 vaccination
    Journal Article

    Sawant, D. A.; Razmaria, A. A.; Pandit-Taskar, N.
    Radiology Case Reports (2023)

    Fulltext@MSK | Save
  • Management of immune-related cutaneous adverse events with dupilumab
    Journal Article

    Kuo, A. M. S.; Gu, S.; Stoll, J.; Moy, A. P.; Dusza, S. W.; Gordon, A.; Haliasos, E. C.; Janjigian, Y.; Kraehenbuehl, L.; Quigley, E. A.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • A plain language summary of the CheckMate 649 study: Nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
    Review

    Janjigian, Y. Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. C.; Liu, T.; more...
    Future Oncology (2023)

    Fulltext@MSK | Save
  • Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
    Journal Article

    Nabbi, A.; Danesh, A.; Espin-Garcia, O.; Pedersen, S.; Wellum, J.; Fu, L. H.; Paulson, J. N.; Geoerger, B.; Marshall, L. V.; Trippett, T.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Journal Article

    Lin, D.; Nguyen, H.; Shah, R.; Qiao, Y.; Hartman, J.; Sugarman, R.
    Gastric Cancer (2023)

    Fulltext@MSK | Save
  • Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study
    Journal Article

    Chan, J. S. K.; Lee, S.; Kong, D.; Lakhani, I.; Ng, K.; Dee, E. C.; Tang, P.; Lee, Y. H. A.; Satti, D. I.; Wong, W. T.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save
  • The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study
    Journal Article

    Lev-Ari, S.; Serzan, M.; Wu, T.; Ip, A.; Pascual, L.; Sinclaire, B.; Adams, S.; Marafelias, M.; Ayyagari, L.; Gill, S. K.; more...
    Cancer (2023)

    Fulltext@MSK | Save